Tirzepatide activates two receptors simultaneously — producing average weight loss of 22% in clinical trials. More effective than semaglutide. Doctor-prescribed, delivered to your door.
Takes 5 minutes. Provider review within 48 hours.
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide activates both pathways simultaneously — producing superior appetite suppression, better blood sugar control, and greater fat loss.
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP (dual) | GLP-1 only |
| Average weight loss | 20-22% | 14-15% |
| Dosing | Weekly injection | Weekly injection or daily pill |
| Best for | Maximum results, type 2 diabetes | First-line GLP-1 treatment |
| Cost at Zera Health | From $294/mo | From $194/mo |
Most patients see significant appetite reduction within 1-2 weeks. Average weight loss is 5-10% in the first 3 months, with full results at 12-18 months. Side effects are similar to semaglutide (primarily nausea, managed with gradual dose titration).
Complete a free 5-minute assessment. A licensed Zera Health provider will review your case within 48 hours.
Start Free Assessment